ESMO 2023 | The future of ctDNA as an indicator of colorectal cancer recurrence at ESMO 2023

Julien Taieb, MD, PhD, Paris Descartes University, Paris, France, highlights the need for future studies evaluating the use of circulating tumor DNA (ctDNA) as an indicator of disease recurrence in post-resection colorectal cancer. Randomized, prospective clinical trials are needed to confirm ctDNA’s efficacy for this use. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.